Tapering Multiple Benzodiazepine Drugs study through investigating Cognition and Risk of Side Effects for Depression

Tapering Multiple Benzodiazepine Drugs study through investigating Cognition and Risk of Side Effects for Depression - Tapering Multiple Benzodiazepine Drugs study through investigating Cognition and Risk of Side Effects for Depression

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026499

Enrollment

Registered

2017-04-01

Start date

2015-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

depression

Interventions

Tapering of anti-anxiety Agents or hypnotics benzodiazepines. If the patient take anti-anxiety agents or hypnotics of benzodiazepine convert diazepam 15mg and above or two kinds, the subject is study

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with major depression who diagnosed by DSM-5 and take anti-anxiety agents or hypnotics of benzodiazepine.

Exclusion criteria

Exclusion criteria: Patients who contract disease affecting cognitive disfunction, for example epilepsy, alcohol dependence syndrome and so on. Pregnant patients.

Design outcomes

Primary

Measure	Time frame
.Nerurocognitive battery	—

Secondary

Measure	Time frame
.Cognitive Failures Questionnaire .Hamilton depression scale .Athens insomnia scale .State-Trait Anxiety Inventory .Social Adaptation Self-evaluation Scale .the clinical withdrawal assessment scale for benzodiazepines	—

Countries

Japan

Contacts

Public ContactYosuke Koshikawa

Kansai medical university The department of neuropsychiatry

koshikay@takii.kmu.ac.jp06-6992-1001

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026